SEC Company Response from Avalo Therapeutics, (AVTX) — Jan 15, 2026
Avalo Therapeutics, Inc.
Date: Jan. 15, 2026 · CIK: 0001534120 · Accession: 0001104659-26-003896
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292614
Letter
Avalo Therapeutics, Inc.
1500 Liberty Ridge Drive, Suite 321
Wayne, Pennsylvania 19087
January 15, 2026
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: Avalo Therapeutics, Inc.
Registration Statement on Form S-3 (File No. 333-292614)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), Avalo Therapeutics, Inc. (the " Company ") hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-292614) (the " Registration Statement "), be accelerated by the Securities and Exchange Commission to 9:00 a.m. Eastern time, on January 20, 2026, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
We request that we be notified of such effectiveness by a telephone call to Jennifer Porter of Goodwin Procter LLP at (445) 207-7806 and that such effectiveness also be confirmed in writing.
Very truly yours,
Avalo Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Avalo Therapeutics, Inc. 1500 Liberty Ridge Drive, Suite 321 Wayne, Pennsylvania 19087 January 15, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Avalo Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-292614) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), Avalo Therapeutics, Inc. (the " Company ") hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-292614) (the " Registration Statement "), be accelerated by the Securities and Exchange Commission to 9:00 a.m. Eastern time, on January 20, 2026, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. We request that we be notified of such effectiveness by a telephone call to Jennifer Porter of Goodwin Procter LLP at (445) 207-7806 and that such effectiveness also be confirmed in writing. Very truly yours, Avalo Therapeutics, Inc. By: /s/ Christopher Sullivan Name: Christopher Sullivan Title: Chief Financial Officer cc: Rachael Bushey, Goodwin Procter LLP Jennifer Porter, Goodwin Procter LLP Jesse Fishman, Goodwin Procter LLP